Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Gene Chip Technology Identifies Sepsis

By HospiMedica staff writers
Posted on 19 Jan 2007
Gene chip technology shows potential for identifying life-threatening blood infections, suggests a new study. More...


Based on studies in mice, researchers at Washington University School of Medicine (St. Louis, MO, USA) propose that the genetic profiles of patients' blood could accurately distinguish sepsis from widespread non-infectious inflammation 94% of the time. The molecular profiles measure differences in patterns of gene expression that are unique to sepsis versus non-infectious inflammation.

The researchers simulated illness in four groups of mice: each of three groups had a varying severity of sepsis and a fourth had systemic non-infectious inflammation. Using microarrays--also known as gene chips--they created molecular profiles based on the abundance of messenger RNA expressed in immune cells taken from the blood of the sick mice. These profiles were compared with profiles from the blood of control mice.

The researchers looked at the activity of thousands of genes 24 hours after the onset of sickness, with the goal of identifying all the genes that might be markers of inflammation and infection. They found small increases in gene expression among hundreds of genes, but it was not the magnitude of change in gene expression that accurately distinguished sepsis from systemic inflammation. Instead, it was the pattern of changes in gene expression that proved to be important. The study was published in the November 2006 issue of the Journal of the American College of Surgeons.

"Our findings hold out hope that scientists could develop a simple bedside blood test that would greatly speed the diagnosis of sepsis,” said lead author J. Perren Cobb, M.D., director of Washington University's Center for Critical Illness and Health Engineering. "We could in a few hours determine if a patient had a blood infection and treat them right away.”



Related Links:
Washington University School of Medicine

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.